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Neurodevelopmental evaluation 
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these concerns.(1,2,10) The guideline is not context-specific and 
serves as a universal tool to facilitate clinical decision-making 
based on best practice evidence.(4,11) The guideline uses a risk-
stratification approach with a clinical algorithm, including a com-
bination of developmental surveillance, screening and evaluation 
aimed at the early identification of developmental delays.(1,2,4,10) 
By extension, the successful implementation of the guideline 
also results in the appropriate referral of children with develop-
mental delays to intervention therapies, including physiother-
apy, occupational therapy and speech therapy, as well as for 
psychological and educational support – to optimise their 
developmental outcome.(1,12-14) 
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ABSTRACT
INTRODUCTION
There is substantial evidence that congenital heart disease 
(CHD) survivors are at higher risk for developmental delays 
than the general population.(1-3) For this reason, neurodevelop-
ment has become one of the most important outcomes being 
investigated in children with CHD.(1,2,4) As many as half of 
children with CHD present with neurodevelopmental delays 
characterised by mild impairments across multiple domains, 
including deficits in gross and fine motor skills, cognition and 
language, and inattention, impulsivity, impaired executive func-
tion and psychosocial problems.(5-8) For many parents, over 
time, the neurodevelopmental difficulties faced by their child 
outweigh the daily burden caused by their heart disease.(9) 
Developmental delays also have a high cost to society, with 
costs escalating considerably when the need for developmental 
intervention is not met and developmental delays are not 
addressed effectively.(10)
The American Heart Association (AHA) published a guideline 
targeting the evaluation and management of neurodevelop-
ment in the CHD population in 2012, in an attempt to address 
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The awareness of the paediatric cardiac care community in 
South Africa (SA) of the 2012 AHA guidelines is unknown. This 
study aimed to determine the neurodevelopmental evaluation 
and referral practices of practitioners treating children with 
CHD in central SA, as well as practitioners’ awareness of the 
2012 AHA guideline.
MATERIALS AND METHODS 
Information on practitioner characteristics, awareness of the 
2012 AHA guideline, and neurodevelopmental evaluation and 
referral practices were collected using a questionnaire. The 
questionnaire used in a survey to determine the implementa-
tion of the 2012 AHA guideline by cardiac care practitioners 
in the United States (US), was adapted and expanded.(2,4) 
Response options to questions on clinical practice settings were 
adapted to the South African context. 
A question was added under the developmental screening 
section to explore practitioners’ use of web-based applications 
for developmental screening. It was deemed important to 
explore this as a possible means of providing remote develop-
mental care. Three further questions were added under the 
referral section to explore practitioners’ views on the acces-
sibility and barriers to intervention therapies. The content 
validity of the questionnaire was established by a physiotherapist 
familiar with the 2012 AHA guideline and experienced in the 
assessment of neurodevelopment in children with CHD in the 
South African context. 
Forty-five practitioners, including general paediatricians (n=38), 
paediatric cardiologists (n=4) and cardiothoracic surgeons 
(n=4), practising in the Free State and/or Northern Cape 
provinces of SA were recruited into this observational 
descriptive study. No sampling method was used due to the 
small population. Practitioners were excluded if they did not 
treat children with CHD. 
Ethical clearance was obtained from the Health Research Ethics 
Committee of the University of the Free State (UFS-
HSD2017/1271). Participation was voluntary and completing 
and submitting the online survey provided informed consent. 
Confidentiality of participant information was maintained. 
An introductory email was sent to 45 practitioners explaining 
the purpose of the survey, the informed consent procedure and 
the time required to complete the questionnaire. An open 
access copy of the 2012 AHA guideline was included in the 
email. The email contained a link to the questionnaire, with an 
access password. This was a closed survey, and was accessible 
by email invitation only. The survey was created and managed 
by an online survey platform (EvaSys) hosted by the University 
of the Free State. Completed surveys were submitted elec-
tronically and participant responses were automatically captured 
in an EXCEL spreadsheet. Once participants submitted their 
questionnaire, the survey became inaccessible, preventing 
multiple submissions. The survey remained open for 6 weeks 
and email reminders were sent out to non-respondents. 
Statistical analysis was done by the Department of Biostatistics 
at the University of the Free State. Descriptive statistics for 
the categorical participant responses are summarised using 
frequencies with percentages. 
RESULTS 
Twenty-one practitioners responded to the survey (response 
rate of 46.7%). A practitioner (n=1) was excluded who did not 
treat children with CHD. The responses from 20 practitioners, 
including general paediatricians (n=14), paediatric cardiologists 
(n=4) and cardiothoracic surgeons (n=2), were included in the 
analysis. The highest response rate was from the paediatric 
cardiologists (100%), with the lowest response from the general 
paediatricians (36.8%). Most of the practitioners (n=13; 65%) 
had been practising in their specialised field for more than a 
decade. Most practitioners (n=17; 85%) practised in both the 
public and private healthcare setting. Half of the practitioners 
(n=10; 50%) had more than 25 children with CHD under their 
care, with the paediatric cardiologists (n=4, 100%) carrying 
the highest load – with more than 50 children under their 
care (Table I).
Most practitioners (n=18; 90%) felt that having neurodevelop-
mental evaluation and management guidelines for children with 
CHD was “somewhat” or “very important”. Despite this view, 
the majority (n=16; 80%) were unaware of the 2012 AHA 
guideline. Awareness was lowest amongst general paediatri-
cians (n=1; 7.1%). The vast majority of practitioners (n=18; 
94.7%) did not risk stratify children with CHD in line with the 
2012 AHA guideline (Table II). 
Most practitioners (n=15; 75%) routinely performed develop-
mental surveillance. In addition to their own surveillance, several 
practitioners (n=7; 46.7%) also referred children to an occu-
pational therapist for developmental surveillance. Thirteen 
practitioners (65%) reported routinely referring children with 
CHD for developmental screening. Children were referred for 
screening most often at all care visits (n=15; 75%) and at 6 
months of age (n=5; 25%). A single practitioner (5%) used 
electronic web-based applications for screening (Table II).
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On the identification of developmental difficulties, practitioners 
most often referred children to allied health services (n=15; 
75%) and medical specialists, including paediatric neurologists 
and neurodevelopmental paediatricians (n=11; 55%), for formal 
developmental evaluation. Less than a quarter (n=4; 20%) of 
practitioners referred children to an interdisciplinary clinic for 
developmental evaluation. Children were usually referred for 
formal developmental evaluation during infancy (n=14; 70%) 
and in the pre-school years (n=9; 45%). Referrals were usually 
based on the practitioner’s own concerns about the child’s 
development (n=17; 85%) and/or noted parental concerns 
(n=16; 80%). Most practitioners (n=15; 75%) referred children 
diagnosed with a genetic disorder for formal developmental 
evaluation (n=15; 75%). Only eight practitioners (40%) 
reported that their referrals for formal developmental 
evaluation were based on abnormal developmental screening 
test results (Table III). Practitioners identified the unavailability 
of medical specialists including paediatric neurologists and 
neurodevelopmental paediatricians (n=8; 40%), and the 
distances families have to travel to access healthcare services 
(n=8; 40%) as the main barriers to formal developmental 
evaluation (Table IV).
When referring children to allied health services, practitioners 
usually referred children to occupational therapy (n=100%), 
followed by physiotherapy (n=15; 75%) and then speech 
therapy (n=14; 70%). Only three practitioners (15%) referred 
children to a psychologist. Practitioners felt that the unavail-
ability of therapy services (n=15; 75%), the distances families 
have to travel to access therapy (n=15; 75%) and the time and 
financial cost to parents in having to take their children to 
therapy (n=8; 40%), were barriers to accessing intervention 
therapies (Table IV).
DISCUSSION
Despite most practitioners indicating that having neuro-
developmental evaluation and management guidelines for 
children with CHD was important, most (80%) were unaware 
of the 2012 AHA guideline. Awareness was lowest among the 
general paediatricians (n=1; 7.1%). A similar lack of awareness 
of 79% was reported in the US survey.(4) Several factors could 
explain this lack of awareness. The guideline was published in a 
cardiovascular journal which may have meant it was less likely 
to be read by general paediatricians.(4) Paediatric cardiologists 
and cardiothoracic surgeons are primarily focused on the 
cardiovascular health of the child with CHD, and may be 
unaware of or overlook the importance of the child’s neuro-
developmental outcome, as a measure of the success of their 
cardiac interventions.(2,8,15) The fact that the guideline is con-
sidered “American”, despite its universal relevance, may also 
have deterred South African practitioners from reading it.
Paediatric cardiologists and cardiothoracic surgeons are pri-
marily responsible for the care provided to children with CHD 
in South Africa. The shortage of paediatric cardiologists in the 
country makes it highly probable that many children with CHD 
are cared for by general paediatricians.(16,17) The poor response 
from general paediatricians (36.8%) may indicate that they are 
either not treating children with CHD and/or that they are 
unaware of the developmental risks faced by these children.
Only three-quarters of practitioners performed routine 
developmental surveillance at every visit to identify those 
children at risk for developmental delays.(11) Cardiothoracic 
surgeons performed no developmental surveillance. This is 
considered a missed opportunity, as they are ideally situated 
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TABLE I: Participant characteristics.
Variable  Frequency (%) (n=20)
Medical speciality 
General paediatrician 14 (70%)
Paediatric cardiologist 4 (20%)
Cardiothoracic surgeon 2 (10%)
Survey response rate per medical speciality 
Pharmacological concepts
14 out of 38 
(36.8%)
Solutions: compositions and therapy 4 out of 4 (100%)
Fluid balance and assesment 2 out of 4 (50%)
Years of clinical practice in current speciality 
<5 years 2 (10%)
5-10 years 5 (25%)
11-15 years 2 (10%) 
>15 years 11 (55%)
Location of clinical practice* 
Public health sector 3 (15%)
Academic or university-affi liated hospital 5 (25%)
Public health sector and academic or 
university-affi liated hospital
3 (15%)
Private health sector 3 (15%)
Public and private health sector 2 (10%)
Public and private health sector; and 
university-affi liated hospital
4 (20%)













TABLE I1: Survey response of practitioners (Part I Awareness of the 2012 AHA guideline and surveillance practices).









Number of children with CHD under their care 
< 10 7 (35%) 6 (42.9%) 0 1 (50%)
10-25 3 (15%) 3 (21.4%) 0 0
26-50 3 (15%) 2 (14.3%) 0 1 (50%)
> 50 7 (35%) 3 (21.4%) 4 (100%) 0
Importance of neurodevelopmental evaluation and management guidelines for CHD 
Very important 14 (70%) 8 (57.1%) 4 (100%) 2 (100%)
Somewhat important 4 (20%) 4 (28.6%) 0 0
Not important 0 0 0 0
Unsure 2 (10%) 2 (14.3%) 0 0
Awareness of the 2012 AHA guideline on evaluation and management of neurodevelopment in CHD 
Yes 4 (20%) 1 (7.1%) 2 (50%) 1 (50%)
No 16 (80%) 13 (92.9%) 2 (50%) 1 (50%)
DEVELOPMENTAL SURVEILLANCE
Identifying children at risk or with developmental problems though observation, identifi cation of parental concerns and taking a 
comprehensive developmental history.
Routinely perform developmental surveillance in their clinical practice 
Yes 15 (75%) 12 (85.7%) 3 (75%) 0
No 5 (25%) 2 (14.3%) 1 (25%) 2 (100%)
Healthcare service provider performing the surveillance*
(n=15) (n=12) (n=3) (n=0)
Self 15 (100%) 12 (100%) 3 (100%) 0
Paediatric neurologist 1 (6.7%) 1 (8.3%) 0 0
Neurodevelopmental paediatrician 4 (26.7%) 2 (16.7%) 2 (66.7%) 0
Physiotherapist 4 (26.7%) 2 (16.7%) 2 (66.7%) 0
Occupational therapist 7 (46.7%) 6 (50%) 1 (33%) 0
Speech therapist 4 (26.7%) 3 (25%) 1 (33%) 0
Psychologist 0 0 0 0
Risk-stratify children with CHD according to 2012 AHA guideline 
(n= 19) (n=13) (n=4) (n=2)
Yes 1 (5.3%) 1 (7.7%) 0 0
No 18 (94.7%) 12 (92.3%) 4 (100%) 2 (100%)
DEVELOPMENTAL SCREENING
The administration of a brief standardised tool to identify child at risk of or presenting with a developmental delay.
Children with CHD are routinely referred for developmental screening 
Yes 13 (65%) 8 (57.1%) 4 (100%) 1 (50%)
No 7 (35%) 6 (42.9%) 0 1 (50%)
Ages at which children are referred for developmental screening*
3 months 3 (15%) 2 (14.3%) 1 (25%) 0
6 months 5 (25%) 3 (21.4%) 2 (50%) 0
9 months 2 (10%) 2 (14.3%) 0 0
12 months 4 (20%) 3 (21.4%) 1 (25%) 0
18 months 4 (20%) 3 (21.4%) 1 (25%) 0
24 months 3 (15%) 3 (21.4%) 0 0
30 months 3 (15%) 3 (21.4%) 0 0
48 months 2 (10%) 2 (14.3%) 0 0
All care visits 15 (75%) 11 (78.6%) 3 (75%) 1 (50%)
Make use of electronic and web-based applications for developmental screening
Yes 1 (5%) 1 (7.1%) 0 0
No 16 (80%) 11 (78.6%) 4 (100%) 1 (50%)
Feel it is not applicable 3 (15%) 2 (14.3%) 0 1(50%)
*Multiple category responses permitted. CHD = Congenital heart disease.
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to identify those children at high risk for developmental delays 
due to cardiac surgery-related factors such as prolonged 
cardiopulmonary bypass,(18,19) the need for cardiopulmonary 
resuscitation,(20) post-operative seizures,(21) and prolonged post-
operative hospital length of stay.(10)
Risk-stratification serves to identify those children with CHD 
considered to be at high risk for developmental delay, and 
who should be referred directly for formal developmental 
evaluation.(2) Only 5.3% of practitioners risk stratified children 
using the criteria set out in the 2012 AHA guideline. This was 
considerably lower than the reported 25% of practitioners 
risk-stratifying children in the US survey.(4) Referral for formal 
developmental evaluation tended to be based on practitioners’ 
own personal or reported parental concerns about the child’s 
CHILDREN WITH CHD
TABLE II1: Survey response of practitioners (Part II Developmental evaluation).










Comprehensive process of detailed evaluation and testing aimed at identifying the specifi c developmental delay or disorder.
Frequency at which children who are identifi ed as being developmentally at-risk are referred for formal medical evaluation 
Never 0 0 0 0
Rarely (<25%) 4 (20%) 2 (14.3%) 1 (25%) 1 (50%)
Sometimes (20-25%) 6 (30%) 5 (35.7%) 1 (25%) 0
Most of the time (50-75%) 6 (30%) 4 (28.6%) 2 (50%) 0
Almost always (>75%) 4 (20%) 3 (21.4%) 0 1 (50%)
Referrals to the following healthcare service providers for formal developmental evaluations* 
Special medical evaluations (neurologist and 
neuroimaging)
11 (55%) 8 (57.1%) 2 (50%) 1 (50%)
Allied health (physio, occupational and speech therapy) 15 (75%) 9 (64.3%) 4 (100%) 2 (100%)
Interdisciplinary high-risk clinics 4 (20%) 2 (14.3%) 2 (50%) 0
Perform the evaluation themselves 7 (35%) 6 (42.9%) 1 (25%) 0
Age period children are referred for formal developmental evaluation*
Neonatal period 3 (15%) 3 (21.4%) 0 0
Infancy 14 (70%) 10 (71.4%) 4 (100%) 0
Pre-schooler 9 (45%) 7 (50%) 1 (25%) 1 (50%)
Scholar 3 (15%) 2 (14.3%) 1 (25%) 0
Adolescence 1 (5%) 1 (7.1%) 0 0
Transition to adulthood 1 (5%) 1 (7.1%) 0 0
Circumstances under which children are referred for formal developmental assessment*
Parental concerns about development 16 (80%) 11 (78.6%) 3 (75%) 2 (100%)
Own concerns about development 17 (85%) 12 (85.7%) 4 (100%) 1 (50%)
Based on developmental screening test results 8 (40%) 7 (50%) 1 (25%) 0
Children underwent open heart surgery in infancy 4 (20%) 3 (21.4%) 0 1 (50%)
Children’s cyanotic lesions who did not undergo surgery 
in infancy
5 (25%) 4 (28.6%) 0 1 (50%)
Presence of a genetic abnormality or syndrome 15 (75%) 10 (71.4%) 3 (75%) 2 (100%)
CHD with comorbidity** 12 (60%) 9 (64.3%) 2 (50%) 1 (50%)
Children considered to be developmentally at-risk are referred for developmental evaluation*
Interdisciplinary evaluation 9 (45%) 9 (64.3%) 0 0
Medical evaluation (genetic testing and neuro-imaging) 10 (50%) 7 (50%) 2 (50%) 1 (50%)
Allied health services (physio, occupational and 
speech therapy)
11 (55%) 6 (42.9%) 3 (75%) 2 (100%)
Other 1 (5%) 0 1 (25%) 0














development. Risks specifically related to CHD itself, such as 
open-heart surgery in infancy and cyanotic lesions, only 
accounted for around a quarter of the referrals for formal 
developmental evaluation. Referral practices tended to be 
reactive, based on the presence of developmental problems or 
noted concerns, rather than proactively based on specific 
CHD-related risks. This would suggest that practitioners were 
unaware of the specific CHD-related developmental risks and 
the criteria for referral for formal developmental evaluation.(4) 
The lack of risk stratification practices in the current study 
TABLE IV: Survey response of practitioners (Part III Developmental evaluation and access to intervention therapies).










Detailed evaluation and testing using a comprehensive, standardised developmental assessment tool aimed at making a developmental 
diagnosis and planning care.
Are the required medical specialists available to complete formal developmental evaluations?
Yes 12 (60%) 8 (57.1%) 2 (50%) 2 (100%)
No 4 (20%) 2 (14.3%) 2 (50%) 0
Do not know 4 (20%) 4 (28.6%) 0 0
Reasons for not referring children for formal developmental evaluation* 
Family resistance 0 0 0 0
Unaware of recommended referral guidelines 5 (25%) 4 (28.6%) 0 1 (50%)
Medical specialists required are not available 8 (40%) 5 (35.7%) 3 (75%) 0
Children already accessing developmental care 3 (15%) 1 (7.1%) 0 2 (100%)
Children already accessing intervention therapies 6 (30%) 5 (35.7%) 0 1 (50%)
Financial concerns of the family 4 (20%) 4 (28.6%) 0 0
Travelling distances for families to access services 8 (40%) 6 (42.9%) 2 (50%) 0
Other 2 (10%) 1 (7.1%) 1 (25%) 0
Are parents and primary care providers informed of the need for ongoing screening for children identifi ed to be at risk of 
developmental diffi culties?*
Yes 16 (80%) 10 (71.4%) 4 (100%) 2 (100%)
No 4 (20%) 4 (28.6%) 0 0
ACCESS TO INTERVENTION THERAPIES
Early intervention therapies include physiotherapy, occupational therapy and speech therapy services. Children may additionally 
require the services of a psychologist.
Intervention therapies that children at risk or presenting with developmental delays are referred to*
Physiotherapist 15 (75%) 9 (64.3%) 4 (100%) 2 (100%)
Occupational therapist 20 (100%) 14 (100%) 4 (100%) 2 (100%)
Speech therapist 14 (70%) 9 (64.3%) 3 (75%) 2 (100%)
Psychologist 3 (15%) 3 (21.4%) 0 0
Distance, on average, parents with children with CHD must travel to access intervention therapies and child support services 
Less than 50 km 4 (23.5%) 4 (36.4%) 0 0
Greater than 50 km 13 (76.5%) 7 (63.6%) 4 (100%) 2 (100%)
Perceived barriers limiting access of children and their families to intervention therapies*
Availability of therapy services 15 (75%) 11 (78.6%) 4 (100%) 0
Traveling distance to therapy services 15 (75%) 9 (64.3%) 4 (100%) 2 (100%)
Parents feel it is unnecessary, their child is doing well 7 (35%) 6 (42.9%) 1 (25%) 0
Cost of early intervention therapies 5 (25%) 4 (28.6%) 1 (25%) 0
Time required from parents to take children to therapy 8 (40%) 5 (35.7%) 2 (50%) 1 (50%)
Time required to adhere to home exercise programmes 8 (40%) 6 (42.9%) 1 (25%) 1 (50%)
Loss of income when taking child therapies 8 (40%) 7 (50%) 1 (25%) 0
Other (siblings at home) 2 (10%) 1 (7.1%) 1 (25%) 0
*Multiple category responses permitted.
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would mean that a considerable number of children at high risk 
for developmental delay were not being referred early for 
formal developmental evaluation. Late referral for formal 
developmental evaluation would, in turn, also result in the 
delayed referral to intervention therapies. These findings are 
consistent with those of the US survey.(4) 
The 2012 AHA guideline recommends that children with 
CHD undergo periodic developmental screening with a brief 
standardised screening tool at 9, 18, 30 and 48 months.(2,11) 
Only 65% of practitioners referred children for developmental 
screening. Screening practices were extremely variable, with 
referral occurring most often (≤25%) at 6, 12 and 18 months 
of age. Very few children (≤ 15%) were referred for develop-
mental screening at or after the age of 2 years. These screening 
practices are likely to result in children with mild develop-
mental delays, behavioural problems and inattention being 
missed.(1,10) Contrastingly, many practitioners (n=15; 75%) 
reported referring children for developmental screening at 
every care visit. This screening practice would unnecessarily 
increase the workload on already over-extended and under-
staffed healthcare services, and would furthermore limit the 
number of children who could be accommodated for 
developmental screening.(17,22) Referral for developmental 
screening in the current study was far lower than the 90% of 
practitioners in the US survey who reported regularly refer-
ring children for developmental screening. US practitioners 
also referred more children aged two years and older for 
developmental screening.(4)
A single practitioner reported using electronic web-based 
developmental screening applications. Neurodevelopmental 
experts are of the opinion that it has become imperative to 
consider the use of innovative technologies to facilitate remote 
developmental screening and therapy interventions in the 
CHD population – to counteract the high loss to develop-
mental follow-up.(12,23-26) Electronic developmental screening 
questionnaires could be completed by parents at home and 
sent on to the practitioner to facilitate remote screening of the 
child’s developmental status.(27)
Less than a quarter of practitioners (n=4; 20%) referred at-risk 
children for formal developmental evaluation, which would 
include the administration of a comprehensive, standardised 
developmental test.(2) Children were referred to allied health 
services (n=15; 75%) and to medical specialists such as a 
paediatric neurologists or neurodevelopmental paediatricians 
(n=11; 55%) for formal developmental evaluation. Based on 
local experience it would be unlikely that a comprehensive, 
standardised developmental test would be administered at 
formal developmental evaluations, due to time constraints, a 
lack of testing expertise and the unavailability of these expen-
sive imported developmental tests. Children were rarely 
referred for developmental evaluation as scholars or adoles-
cents. This is of concern, as one in three children with CHD 
have educational concerns,(7,21) and up to 50% of school-aged 
children are reported to require intervention therapies and 
remedial educational services.(6,7,28)
Around a third of practitioners (n=6) did not refer children for 
formal developmental evaluation if they were already accessing 
intervention therapies. The US survey had a similar finding.(4) 
Intervention therapies are important in effectively addressing 
developmental delays, but do not replace the need for con-
current formal developmental evaluation.(4) Barriers to formal 
developmental evaluation are consistent with previous reports, 
and include a lack of access to the necessary medical spe-
cialists, including paediatric neurologists and neurodevelop-
mental paediatricians (n=8; 40%), and the distance children and 
their families have to travel to access services (n=8; 40%).(4,14,29)
Only 20% of practitioners referred children to an interdisciplinary 
clinic for developmental evaluation, despite an interdisciplinary 
approach being strongly advocated.(13,14) The prohibitive infra-
structure and human resource costs of establishing dedicated 
cardiac neurodevelopmental clinics have resulted in the cardiac 
care community in both the US and Canada recommending 
that existing, well established interdisciplinary high-risk clinics 
be used for cardiac neurodevelopmental follow-up.(6,12-14) The 
lack of utilisation of existing high-risk interdisciplinary clinics 
in the current study is of concern, as this is likely to be the 
only feasible option for providing cardiac neurodevelopmental 
follow-up in South Africa.
Children presenting with developmental delays were referred 
to occupational therapy (100%), physiotherapy (75%) and 
speech therapy (70%). Children were mostly screened before 
the age of two years for developmental delays, where motor 
delays and language deficits are known to be more common.(1) 
Screening practices would have suggested greater numbers of 
referrals to physiotherapy and speech therapy to address these 
developmental delays. It must also be considered that the 
referral pattern may reflect the therapy services available to 
children in central South Africa.(30) Children with CHD are at 
increased risk of behavioural and social difficulties, and are 3 - 4 
times more likely to present with inattention and hyperactivity 
than the general population.(2,7,19,21) Only 15% of participants 













of referrals to psychologists may be due to the small number of 
school-aged and adolescent children screened and evaluated 
for developmental and behavioural difficulties. Furthermore, 
psychologists are a very limited resource in the healthcare 
sector globally.(31,32) 
Perceived barriers to accessing intervention therapies included 
the distance families had to travel to access therapy, the time 
required from parents to take their child for therapy, the time 
required to adhere to the prescribed home exercise pro-
grammes, and the loss of income suffered by parents who had 
to take their children to therapy appointments. Most parents 
(76.5%) stayed more than 50 kilometres from their closest 
cardiac centre, where intervention therapies were offered. 
The noted barriers are consistent with those in the scant 
published literature on the feasibility and practicability of pro-
viding developmental interventions to children with CHD.(25,26)
Limitations
The study findings need to be interpreted in the light of several 
limitations. Though the survey response rate at 46.7% is higher 
than the reported average response rate of 33% for online 
surveys, the sample size was small.(33) Reasons for the non-
responses may have included incorrect email contact addresses, 
emails being caught up in spam filters, practitioners not 
considering the survey to be of interest or of relevance to 
them, and practitioners not having the time to complete the 
survey due to their already overburdened work schedules.(34,35)
The findings are specific to the population of practitioners in 
central South Africa and may not be generalisable to prac-
titioners caring for children with CHD in South Africa or 
globally. The small sample size limited the ability to compare 
the responses for the various practitioner categories. The 
online survey was only available for 6 weeks, which may have 
limited the number of responses received. 
Recommendations 
A national survey in a larger sample of cardiac care practitioners 
is needed to better determine practitioners’ awareness of the 
2012 AHA guidelines, as well as their neurodevelopmental 
evaluation and referral practices. The feasibility of remote web-
based developmental screening applications accessible via a 
smartphone, requires further investigation. 
CONCLUSION 
Most practitioners in central South Africa are unaware of 
the 2012 AHA guideline and the developmental risks faced 
by children with CHD. Current evaluation practices are sub-
optimal and are likely to result in children with CHD at high 
risk for developmental delays not being identified and referred 
for early formal developmental evaluation and intervention 
therapies. Strategies to raise awareness of the 2012 AHA 
guideline among cardiac care practitioners need to be devised.
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